2. 乳腺癌侵袭性导管瘤 Bini等[8]用蛋白质组学对乳腺癌侵袭性导管瘤(breast invasive ductal carcinoma)进行研究,发现有32种蛋白质仅在导管瘤组 …www.cnbiotech.com|基于3个网页 例句 释义: 全部,乳腺浸润性导管癌,乳腺癌侵袭性导管瘤 更多例句筛选 1. The expression of P63 in breast invasive ductal carci...
5)invasive ductual breast carcinoma浸润性乳腺导管癌 6)invasive ductal carcinoma乳腺导管浸润癌 1.Expressions of Bcl-2 and PCNA ininvasive ductal carcinomaof breast and their clinical significance;凋亡抑制基因Bcl-2和增殖细胞核抗原在乳腺导管浸润癌中的表达及意义...
breast invasive carcinoma 来自 国家科技图书文献中心 喜欢 0 阅读量: 26 作者: Nanda Kumar, Yellapu, Madhusudana Pulaganti, Pakala Suresh Babu, Nanda Kumar Yellapu 摘要: P21-activated kinase-1 (PAK1) is an enzyme associated with multiple metabolic networks and different types of cancers. Hence,...
Invasive Ductal Carcinoma Stages Results from these tests will show the stage of your cancer. Staging is the name for the process doctors use to figure out if and how farbreast cancerhas spread. Knowing the stage will help guide your treatment. ...
Invasive micropapillary carcinoma of the breast: high incidence of lymph node metastasis with extranodal extension and its immunohistochemical profile comp... Aims : Invasive micropapillary carcinoma of the breast is an aggressive and distinctive variant of breast cancer. These tumours have a ...
(p = 0.006), higher histologic grade (p = 0.039), larger tumor size (p = 0.029), and AI-assessed higher intratumoral necrosis (p = 0.027) and intratumoral invasive carcinoma (p = 0.040) proportions, were significant factors for successful PDX engraftment (area under ...
Ductal carcinoma in situ (DCIS) represents pre-invasive breast carcinoma. In untreated cases, 25–60% DCIS progress to invasive ductal carcinoma (IDC). The challenge lies in distinguishing between non-progressive and progressive DCIS, often resulting in
DOI:10.1158/0008-5472.CAN-04-1976 Alterations in Vascular Gene Expression in Invasive Breast Carcinoma 来自 掌桥科研 喜欢 0 阅读量: 786 作者:BS Parker,P Argani,BP Cook,E Al,CT Aacr,BS Parker,P Argani,BP Cook,L Han,SD Chartr 摘要: Access the most recent version of this article at: ...
carcinoma in situ (LCIS), where there is both an increased risk of subsequent ipsilateral and contralateral invasive disease23. Second, the true risk of recurrence from the same population of preinvasive tumor cells has probably been overestimated, thereby confounding the potential benefit of ...